Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
16.04. | Shield Therapeutics - Notice of Results | 5 | RNS | ||
21.02. | Shield Therapeutics sinks as strong performance marred by data issues | 7 | Alliance News | ||
21.02. | Shield Therapeutics - Unaudited Full Year Trading Update | 3 | RNS | ||
11.01. | Shield Therapeutics - New CFO to support US traction | 280 | Edison Investment Research | Shield Therapeutics has appointed Santosh Shanbhag as chief financial officer (CFO) and member of the executive leadership team. Mr. Shanbhag was previously the CFO of Nasdaq-listed Akili, which he... ► Artikel lesen | |
09.01. | IN BRIEF: Shield Therapeutics hires former Akili leader as new CFO | 2 | Alliance News | ||
09.01. | Shield Therapeutics - Appointment of new Chief Financial Officer | 1 | RNS | ||
08.12.23 | Shield Therapeutics - Delivering what the doctor ordered | 373 | Edison Investment Research | Shield Therapeutics' US commercialisation efforts continue to gather steam, with prescription volumes gearing up in Q323 (27,750 prescriptions, a 76% sequential growth over Q2 and higher than the combined... ► Artikel lesen | |
07.12.23 | Shield Therapeutics reports strong US progress | 2 | Sharecast | ||
07.12.23 | Shield Therapeutics - Q3 2023 U.S. Commercial Highlights | 1 | RNS | ||
27.11.23 | Shield Therapeutics - PDMR Transaction Notification | 3 | RNS | ||
15.11.23 | Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team | 324 | EQS Group (EN) | Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team 15-Nov-2023 / 07:30 GMT/BST
The issuer is solely... ► Artikel lesen | |
29.09.23 | Shield Therapeutics - Ramped up and heading into a stronger H223 | 496 | Edison Investment Research | Shield Therapeutics' H123 results were largely as expected. Despite the minor operational adjustments with the commercialisation ramp-up, our long-term expectations remain unchanged. H123 revenue of... ► Artikel lesen | |
25.07.23 | Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering | 457 | Dow Jones News | DJ Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
Hardman & Co Research
Hardman & Co Research on Shield Therapeutics (STX): Accrufer Rx momentum gathering
25-Jul-2023... ► Artikel lesen | |
17.05.23 | Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer prescriptions | 408 | Dow Jones News | DJ Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer prescriptions
Hardman & Co Research Hardman & Co Research on Shield Therapeutics (STX): Reassuring 1Q'23 Accrufer... ► Artikel lesen | |
09.05.23 | Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc | 305 | PR Newswire | Premier Miton Group Plc - Form 8.3 - Shield Therapeutics plc
PR Newswire
London, May 9
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON... ► Artikel lesen | |
09.05.23 | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc | 313 | PR Newswire | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
PR Newswire
London, May 9
FORM 8.3
PUBLIC DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES... ► Artikel lesen | |
05.05.23 | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc | 371 | PR Newswire | Killik & Co. LLP - Form 8.3 - Shield Therapeutics Plc
PR Newswire
London, May 5
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT... ► Artikel lesen | |
04.05.23 | Shield Therapeutics - FY23 a key year for business traction | 376 | Edison Investment Research | Shield Therapeutics reported its FY22 preliminary results and Q123 business update, the key emphasis of which was the growing traction of Accrufer in the US following the December 2022 co-commercialisation... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,895 | -0,28 % | BASF und Bayer: Alarmstufe Rot, öffnet sich die Falltür? | Der Dax verliert so langsam den Kontakt zur 18.000er Marke. In den letzten Handelstagen stemmte sich der Index mit aller Macht gegen den Eintritt in eine Korrektur.Doch so langsam muss man sich eben... ► Artikel lesen | |
PFIZER | 23,560 | 0,00 % | Pfizer - mit Seagan soll die Wende kommen | ||
AURORA CANNABIS | 6,290 | +0,48 % | Aurora Cannabis & Canopy Growth: Deshalb ziehen sie an | Die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) haben am Donnerstag plötzlich einen massiven Kurssprung von über +20% vollführt. Das steckt hinter dem rasanten... ► Artikel lesen | |
SANOFI | 91,78 | +0,27 % | JPMORGAN stuft SANOFI auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat Sanofi vor den Zahlen des Pharmakonzerns für das erste Quartal auf "Neutral" mit einem Kursziel von 94 Euro belassen. Analyst Richard Vosser liegt... ► Artikel lesen | |
CANOPY GROWTH | 8,060 | -0,49 % | Spotlight on Canopy Growth: Analyzing the Surge in Options Activity | ||
ASTRAZENECA | 141,15 | +6,45 % | Verhaltene Kauflaune bei Aktie von AstraZeneca plc (64,2491 €) | Wenig Kursbewegung aktuell bei dem Anteilsschein von AstraZeneca plc . Die Aktie notiert derzeit bei 68,39 US-Dollar. Kaum auffällig ist zur Stunde an der Börse der Kurs von AstraZeneca plc . Das Papier... ► Artikel lesen | |
INNOCAN PHARMA | 0,191 | +1,06 % | Innocan Pharma leitet FDA-Zulassungsverfahren für Liposomen-Injektionstherapie gegen chronische Schmerzen ein | Mit der Übermittlung eines Antragsschreibens für ein Pre-IND-Meeting leitet Innocan das behördliche Zulassungsverfahren für seine Technologie der verzögerten
CBD-Freisetzung beim Menschen bei... ► Artikel lesen | |
VIATRIS | 10,735 | +0,37 % | Viatris Announces Product Donations To Direct Relief of More Than 7 Million Doses of Medicine To Support Access to Medicine and Healthcare | Long-standing partnership with Direct Relief assists crisis areas around the worldSTEINHAUSEN, SWITZERLAND / ACCESSWIRE / April 19, 2024 / Viatris Inc. (NASDAQ:VTRS), a global healthcare company, today... ► Artikel lesen | |
TRANSCANNA | 0,017 | -100,00 % | TransCanna Holdings Inc. Announces Closing of Loan Upsize | Vancouver, British Columbia--(Newsfile Corp. - December 22, 2023) - TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) ("TransCanna" or the "Company") today announces that is has entered into a second... ► Artikel lesen | |
BEVCANNA ENTERPRISES | 1,245 | -3,11 % | Bevcanna Enterprises Inc (3): Bevcanna to issue 169,816 shares for debt | ||
KHIRON LIFE SCIENCES | 0,029 | -100,00 % | Khiron Life Sciences Corp.: Khiron Life Sciences Announces Closing of the Sale of Its European Business | Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the... ► Artikel lesen | |
SANTHERA PHARMACEUTICALS | 9,739 | +1,45 % | Santhera Pharmaceuticals Holding AG: Santhera gibt vorläufige ungeprüfte Jahresergebnisse 2023 und ein Business-Update bekannt, gefolgt von der Publikation des Jahresberichts im Mai | Ad-hoc-Mitteilung gemäss Art. 53 KR
Eine Telefonkonferenz findet am 25. April 2024 um 14:30 MESZ / 13:30 BST / 08:30 EDT statt. Einzelheiten dazu am Ende dieser Pressemitteilung.
2023 finanzielle... ► Artikel lesen | |
AMPIO | 0,181 | 0,00 % | Ampio Pharmaceuticals, Inc.: Ampio Pharmaceuticals Received Audit Opinion with Going Concern Explanation | ENGLEWOOD, Colo., April 3, 2024 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) (the "Company" or "Ampio") today announced that, as previously disclosed in its Annual Report on Form... ► Artikel lesen | |
ALLARITY THERAPEUTICS | 1,430 | 0,00 % | Allarity Therapeutics, Inc. - 8-K, Current Report | ||
ELIXINOL WELLNESS | 0,001 | 0,00 % | ELIXINOL WELLNESS LIMITED: Application for quotation of securities - EXL |